Premium
Mesalazine release from a pH dependent formulation: effects of omeprazole and lactulose co‐administration
Author(s) -
Hussain F. N.,
Ajjan R. A.,
Moustafa M.,
Weir N. W.,
Riley S. A.
Publication year - 1998
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1046/j.1365-2125.1998.00762.x
Subject(s) - mesalazine , lactulose , omeprazole , pharmacokinetics , sulfapyridine , metabolite , aminosalicylic acid , pharmacology , medicine , active metabolite , chemistry , gastroenterology , sulfasalazine , ulcerative colitis , disease , organic chemistry
Aims Delayed‐release formulations of mesalazine often rely on the gastrointestinal luminal pH profile to deliver 5‐aminosalicylic acid (5ASA) to the colon. The aim of this study was to examine the influence of luminal pH on mesalazine release.Methods We studied the effect of co‐administration of omeprazole and lactulose on the steady‐state pharmacokinetics of Eudragit S‐coated mesalazine in healthy volunteers.Results No significant changes in urinary or faecal levels of 5ASA or its main metabolite, N ‐acetyl 5ASA, were apparent.Conclusions This study suggests that co‐administration of omeprazole and lactulose does not impair the release of delayed‐release mesalazine.